Risks of transfusion.

Each year, more than 4 million patients receive a blood transfusion in the United States to control symptoms associated with anemia, coagulopathy, thrombocytopenia, or some combination thereof. In each of these cases, the physician and the patient must weigh the potential benefits of the transfusion along with the associated risks. To assess accurately the risk:benefit ratio and to discuss this with the patient, the physician must be familiar with the range of adverse transfusion outcomes and the current estimates of their frequency. Most important, during the past decade the risk profile of transfusion has changed significantly. Transfusion-transmitted disease, although still a rare outcome of transfusion, is no longer an overriding concern in transfusion safety considerations; however, risks such as hemolysis, transfusion-related lung injury, and anaphylaxis continue to represent significant concerns and are relatively more common than the transmission of infectious diseases after transfusion. Against this background, the development of a national hemovigilance system, designed to evaluate more accurately transfusion adverse outcomes in the United States, will require greater precision and reliability in the assessment of adverse transfusion outcomes by clinicians if the proposed benefits of this system are to be realized.

[1]  K. Tadokoro,et al.  Anaphylactic transfusion reactions in haptoglobin‐deficient patients with IgE and IgG haptoglobin antibodies , 2002, Transfusion.

[2]  L. Holness,et al.  Babesia infection through blood transfusions: reports received by the US Food and Drug Administration, 1997-2007. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  H. Marriott,et al.  Volume and Rate in Blood Transfusion for the Relief of Anaemia , 1940, British medical journal.

[4]  O. Gajic,et al.  The accuracy of natriuretic peptides (brain natriuretic peptide and N‐terminal pro‐brain natriuretic) in the differentiation between transfusion‐related acute lung injury and transfusion‐related circulatory overload in the critically ill , 2009, Transfusion.

[5]  S. Glynn,et al.  A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors , 2005, Transfusion.

[6]  C. Silliman,et al.  Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. , 2003, Blood.

[7]  R. Benjamin,et al.  Effective reduction of transfusion‐related acute lung injury risk with male‐predominant plasma strategy in the American Red Cross (2006‐2008) , 2010, Transfusion.

[8]  U. Sachs,et al.  Pulmonary Transfusion Reactions , 2008, Transfusion Medicine and Hemotherapy.

[9]  D. Dwyre,et al.  Transfusion‐associated graft‐versus‐host disease , 2008, Vox sanguinis.

[10]  D. Leiby.  Making sense of malaria , 2007, Transfusion.

[11]  B. B. Morgan,et al.  Anaphylactic transfusion reaction associated with a possible anti-A2m(1). , 2008, Clinical and laboratory haematology.

[12]  E. Strobel.  Hemolytic Transfusion Reactions , 2008, Transfusion Medicine and Hemotherapy.

[13]  K. Lechner,et al.  Posttransfusion purpura , 1986, Klinische Wochenschrift.

[14]  M. Yazer,et al.  The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC , 2004, Transfusion.

[15]  A. Borne,et al.  The Serology of Febrile Transfusion Reactions , 1985, Vox sanguinis.

[16]  L. Simon,et al.  Rossi's Principles of Transfusion Medicine , 2002 .

[17]  E. Vamvakas,et al.  The differentiation of delayed hemolytic and delayed serologic transfusion reactions: incidence and predictors of hemolysis , 1995, Transfusion.

[18]  J. Kelton,et al.  The role of the plasma from platelet concentrates in transfusion reactions. , 1994, The New England journal of medicine.

[19]  J. Bethel,et al.  Estimates of Infectious Disease Risk Factors in U.S. Blood Donors , 1998 .

[20]  R. Dodd.  The risk of transfusion-transmitted infection. , 1992, The New England journal of medicine.

[21]  A. Williams,et al.  Estimates of infectious disease risk factors in US blood donors. Retrovirus Epidemiology Donor Study. , 1997, JAMA.

[22]  H. Haak,et al.  Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases , 1999, Transfusion.

[23]  A E Voytovich,et al.  Transfusion errors in New York State: an analysis of 10 years' experience , 2000, Transfusion.

[24]  N. Soni,et al.  Ten years of hemovigilance reports of transfusion‐related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma , 2009, Transfusion.

[25]  R. Aster,et al.  IMMUNOREACTIONS INVOLVING PLATELETS. V. POST-TRANSFUSION PURPURA DUE TO A COMPLEMENT-FIXING ANTIBODY AGAINST A GENETICALLY CONTROLLED PLATELET ANTIGEN. A PROPOSED MECHANISM FOR THROMBOCYTOPENIA AND ITS RELEVANCE IN "AUTOIMMUNITY". , 1961, The Journal of clinical investigation.

[26]  R. Benjamin,et al.  Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004‐2006) , 2007, Transfusion.

[27]  G. Schiller,et al.  Transfusion‐associated graft‐versus‐host disease in immunocompetent patients: report of a fatal case associated with transfusion of blood from a second‐degree relative, and a survey of predisposing factors , 1993, Transfusion.

[28]  J. Herman,et al.  Acute Hypotensive Transfusion Reactions , 2006 .

[29]  D. Harlan,et al.  Pancreatic islet cell therapy for type I diabetes: understanding the effects of glucose stimulation on islets in order to produce better islets for transplantation , 2007, Journal of Translational Medicine.

[30]  C. Parshuram,et al.  Transfusion-associated graft versus host disease , 2002, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[31]  S. Kleinman,et al.  Emerging infectious disease agents and their potential threat to transfusion safety , 2009, Transfusion.

[32]  A. Eder,et al.  Noninfectious complications of blood transfusion. , 2009, Archives of pathology & laboratory medicine.

[33]  Sally Caglioti,et al.  Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. , 2004, The New England journal of medicine.

[34]  U. Sugg,et al.  Transfusion Transmitted Infections , 1992 .

[35]  Robertson Davenport,et al.  Toward an understanding of transfusion‐related acute lung injury: statement of a consensus panel , 2004, Transfusion.

[36]  C. Hillyer,et al.  The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion‐related acute lung injury risk reduction strategy , 2009, Transfusion.

[37]  A. Brand,et al.  Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: is it time to take precautionary measures? , 2006, Transfusion.

[38]  D. Giacherio,et al.  Use of B‐natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion‐associated circulatory overload , 2005, Transfusion.

[39]  H. Cohen,et al.  Serious hazards of transfusion: a decade of hemovigilance in the UK. , 2006, Transfusion medicine reviews.

[40]  K. Sazama,et al.  Reports of 355 transfusion‐associated deaths: 1976 through 1985 , 1990, Transfusion.